Goldman Sachs
AIM

Goldman Sachs’s AIM ImmunoTech AIM Stock Holding History

Goldman Sachs’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-148
Closed -$38K – 5697
2020
Q1 		$38K Buy
+148
New +$23.2K ﹤0.01% 5078
2016
Q3 		– Hold
0
– -$3K – 7499
2016
Q2 		– Hold
0
– – – 6969
2016
Q1 		– Hold
0
– – – 7021
2015
Q4 		– Sell
-1
Closed -$6.8K – 7111
2015
Q3 		$5K Hold
1
– – ﹤0.01% 7212
2015
Q2 		$6K Buy
+1
New +$12.4K ﹤0.01% 7197
2015
Q1 		– Hold
0
– – – 7006
2014
Q4 		– Hold
0
– – – 7068
2014
Q1 		– Hold
0
– -$6K – 7174
2013
Q4 		– Hold
0
– – – 6602
2013
Q3 		– Hold
0
– – – 6512
2013
Q2 		– Hold
0
– – – 6290

Other funds holding AIM

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
SAMH
Shanda Asset Management Holdings Tortola,, British Virgin Islands $1.85B AUM 36.09% 1-Year Est. Return

Goldman Sachs's AIM Position: Q2 2020 in Review

Goldman Sachs sold out of AIM ImmunoTech (AIM) in Q2 2020, closing a stake of 148 shares — an estimated $38K sold.

Goldman Sachs first reported a position in AIM in Q2 2015 and held it in 3 quarters. The position peaked at $38K in Q1 2020. 22 funds tracked by Wall St. Rank hold AIM as of Q2 2020.

  • Goldman Sachs reported no remaining AIM ImmunoTech position as of Q2 2020 after selling out during the quarter.
  • Goldman Sachs sold 148 AIM ImmunoTech shares in Q2 2020, an estimated $38K.
  • Goldman Sachs first reported a position in AIM ImmunoTech in Q2 2015 and held it in 3 quarters.
  • Goldman Sachs's AIM ImmunoTech position peaked at $38K in Q1 2020.
  • 22 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2020.

Based on Goldman Sachs's 13F filing for Q2 2020, filed 12 Aug 2020.